Kornitzer Capital Management Inc. KS Reduces Holdings in Gilead Sciences, Inc. $GILD

Kornitzer Capital Management Inc. KS reduced its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 4.3% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 334,476 shares of the biopharmaceutical company’s stock after selling 15,010 shares during the period. Kornitzer Capital Management Inc. KS’s holdings in Gilead Sciences were worth $37,127,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the stock. Csenge Advisory Group raised its holdings in Gilead Sciences by 319.0% in the 3rd quarter. Csenge Advisory Group now owns 21,394 shares of the biopharmaceutical company’s stock valued at $2,375,000 after acquiring an additional 16,288 shares during the last quarter. Railway Pension Investments Ltd increased its stake in Gilead Sciences by 3.1% in the third quarter. Railway Pension Investments Ltd now owns 1,415,665 shares of the biopharmaceutical company’s stock valued at $157,139,000 after purchasing an additional 42,200 shares during the last quarter. TriaGen Wealth Management LLC purchased a new position in Gilead Sciences during the third quarter worth about $1,274,000. iA Global Asset Management Inc. boosted its stake in Gilead Sciences by 11.6% in the 3rd quarter. iA Global Asset Management Inc. now owns 221,890 shares of the biopharmaceutical company’s stock worth $24,630,000 after buying an additional 23,046 shares during the last quarter. Finally, Invesco Ltd. grew its holdings in Gilead Sciences by 33.5% in the 2nd quarter. Invesco Ltd. now owns 13,521,228 shares of the biopharmaceutical company’s stock valued at $1,499,098,000 after buying an additional 3,394,330 shares during the period. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Stock Performance

Shares of NASDAQ:GILD opened at $137.78 on Tuesday. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.31 and a current ratio of 1.45. Gilead Sciences, Inc. has a one year low of $93.10 and a one year high of $138.03. The business’s 50-day simple moving average is $124.25 and its 200 day simple moving average is $118.88. The company has a market cap of $170.94 billion, a P/E ratio of 21.36, a PEG ratio of 0.71 and a beta of 0.33.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share for the quarter, beating analysts’ consensus estimates of $2.16 by $0.31. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. The business had revenue of $7.77 billion during the quarter, compared to analyst estimates of $7.42 billion. During the same period last year, the business earned $2.02 EPS. The business’s revenue was up 3.0% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. On average, sell-side analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Insider Transactions at Gilead Sciences

In other news, Director Jeffrey Bluestone sold 5,000 shares of the business’s stock in a transaction dated Friday, November 28th. The shares were sold at an average price of $125.08, for a total value of $625,400.00. Following the completion of the sale, the director owned 8,920 shares of the company’s stock, valued at approximately $1,115,713.60. The trade was a 35.92% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Andrew D. Dickinson sold 3,000 shares of the stock in a transaction dated Thursday, January 15th. The stock was sold at an average price of $124.31, for a total transaction of $372,930.00. Following the transaction, the chief financial officer directly owned 150,503 shares in the company, valued at $18,709,027.93. The trade was a 1.95% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 247,397 shares of company stock valued at $31,986,612 in the last three months. 0.27% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the stock. HSBC increased their price objective on shares of Gilead Sciences from $110.00 to $133.00 and gave the stock a “hold” rating in a report on Wednesday, December 10th. UBS Group increased their price target on shares of Gilead Sciences from $145.00 to $155.00 and gave the stock a “buy” rating in a research note on Monday. TD Cowen boosted their price objective on shares of Gilead Sciences from $115.00 to $125.00 and gave the company a “buy” rating in a research note on Thursday, October 23rd. Scotiabank initiated coverage on Gilead Sciences in a research report on Thursday, November 13th. They issued a “sector outperform” rating and a $140.00 target price on the stock. Finally, Argus lifted their target price on Gilead Sciences from $130.00 to $135.00 and gave the company a “buy” rating in a report on Tuesday, November 4th. One analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $134.52.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.